JJET, China's leading company in the electrophysiology industry, will accelerate the upgrade of industry structure and platform development to better meet unmet clinical needs with the fresh proceeds.
JJET (Chinese: 锦江电子), an innovative leading company in the electrophysiology industry, completed the Series A+ and B rounds of financing recently. The round was jointly invested by Xinda Kunpeng (Chinese: 信达鲲鹏), Guanghua Wutong (Chinese: 光华梧桐), Hangzhou Yuanheng Lizhen (Chinese: 杭州元亨利贞), WEGO (Chinese: 威高集团) and HM Capital (Chinese: 惠每资本). The company completed the Series A financing round led by Hillhouse Capital (Chinese: 高瓴资本) in December 2021. The company has raised more than CNY 700 million in the Series A and B financing rounds.
The funds will be used to advance the clinical trial registration of several heavyweight electrophysiology products and the R&D of the company's subsequent innovative products. JJET will also use this funding to improve its organizational structure and commercialization system and to enhance its competitive advantages in the domestic and global electrophysiology field.
Founded in 1991, JJET is focused on the R&D, production, and marketing of cardiac electrophysiology devices, including the 3Ding Cardiac Mapping System, Electrophysiology Recording System, Cardiac RF Ablation Generator, Irrigation Pump, Electrophysiology Catheters, Ablation Catheters, Neural RF Generator etc. JJET has more than 1,000 institutional users and sales networks all around China. It works tirelessly to achieve scientific and technological advancements.
The company's competitors include APT Medical (Chinese: 惠泰医疗), MicroPort EP (Chinese: 微创电生理) and Synaptic Medical (Chinese: 心诺普医疗).